BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 10554030)

  • 1. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
    Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
    Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
    Li WW; Tong WP; Bertino JR
    Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ; Magee KJ; Russell CA; Canestrari JM
    Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
    Backus HH; Pinedo HM; Wouters D; PadrĂ³n JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
    Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
    Hanlon MH; Ferone R
    Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
    Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
    Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.